Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry

Analytical and Bioanalytical Chemistry

Volumn 382, Issue 7, 2005, Pages 1484-1490

  Brouwers, E E M ^a   Tibben, M M ^a   Joerger, M ^a   Van Tellingen, O ^b   Rosing, H ^a   Schellens, J H M ^b,c   Beijnen, J H ^a,b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anti cancer drugs; GF AAS; Oxaliplatin; Platinum; Quantitative; Validation

Indexed keywords

CLINICAL TRIALS; GF-AAS; OXALIPLATIN; QUANTITATIVE VALIDATION;

ABSORPTION SPECTROSCOPY; ATOMIZATION; DRUG PRODUCTS; GRAPHITE; PLATINUM; SENSITIVITY ANALYSIS; TUMORS; ULTRAFILTRATION;

BODY FLUIDS;

ANTINEOPLASTIC AGENT; GRAPHITE; OXALIPLATIN; PLATINUM COMPLEX;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD; CALIBRATION; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; ULTRAFILTRATION; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CALIBRATION; GRAPHITE; HUMANS; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ATOMIC; ULTRAFILTRATION;

EID: 23244447501     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-005-3302-5     Document Type: Article

References (23)

1. Rosenberg B, Vancamp L, Krigas T (1965) Nature 205:698-699
2. Kelland LR, Farrell NP (2000) Platinum-based drugs in cancer therapy. Humana Press, Totowa, NJ
3. Mathé G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Misset JL (1986) Biomed Pharmacother 40:372-376
4. Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Ann Oncol 9:1053-1071
5. Pendyala L, Creaven PJ (1993) Cancer Res 53:5970-5976
6. Schmidt W, Chaney SG (1993) Cancer Res 53:799-805
7. van Warmerdam LJC, van Tellingen O, Maes RAA, Beijnen JH (1995) Fresenius J Anal Chem 351:777-781
8. Kloft C, Appelius H, Siegert W, Schunack W, Jaehde U (1999) Ther Drug Monit 21:631-637
9. LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA (1977) Biochem Med 18:184-191
10. Meerum Terwogt JM, Tibben MM, Welbank H, Schellens IHM, Beijnen JH (2000) Fresenius J Anal Chem 366:298-302
11. Tibben MM, Rademaker-Lakhai JM, Rice JR, Stewart DR, Schellens JHM, Beijnen JH (2002) Anal Bioanal Chem 373:233-236
12. Vouillamoz-Lorenz S, Bauer J, Lejeune F, Decosterd LA (2001) J Pharm Biomed Anal 25:465-475
13. Merkel U, Wedding U, Roskos M, Hoffken K, Hoffmann A (2003) Exp Toxicol Pathol 54:475-479
14. Bastian G, Barrail A, Urien S (2003) Anticancer Drugs 14:817-824
15. Delord JP, Umlil A, Guimbaud R, Grrgoire N, Lafont T, Canal P, Bugat R, Chatelut E (2003) Cancer Chemother Pharmacol 51:127-131
16. Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, Alafaci E, Dutertre-Catella H, Bastian G (2000) Cancer Chemother Pharmacol 45:157-164
17. Extra JM, Marty M, Brienza S, Misset JL (1998) Semin Oncol 25:13-22
18. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E (2000) Clin Cancer Res 6:1205-1218
19. US Food and Drug Administration (2001) Center for Drug Evaluation and Research, Guidance for Industry, Bioanalytical Method Validation, http://www.fda.gov/cder/guidance/ 4252fnl.pdf
20. Verstraete S, Heudi O, Cailleux A, Allain P (2001) J Inorg Biochem 84:129-135
21. Hann S, Stefanka Z, Lenz K, Stingeder G (2004) Anal Bioanal Chem
22. Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H (2004) Pharm Res 21:891-894
23. Levi F, Metzger G, Massari C, Milano G (2000) Clin Pharmacokinet 38:1-21